Background-Approximately one third of patients with symptomatic aortic stenosis have reduced left ventricular ejection fraction (LVEF) before transcatheter aortic valve replacement. The incidence, predictors, and significance of early LVEF recovery after CoreValve transcatheter aortic valve replacement have not been described. Methods and Results-We studied 156 patients from the CoreValve Extreme and High-Risk trials with LVEF ≤40% at baseline who had 30-day LVEF data. All patients underwent core laboratory echocardiographic assessment of LVEF at baseline, post procedure, discharge, 30 days, 6 months, and 1 year. Early LVEF recovery was defined as an absolute increase of ≥10% in EF at 30 days. One-year outcomes were compared between patients with and without early recovery. Multivariable analysis was performed to determine independent predictors of early recovery. Early LVEF recovery occurred in 62% of patients, generally before discharge. By 30 days LVEF increased >17% compared with baseline in the early recovery group with minimal increase in the no-early recovery group (48.9±8.8% versus 31.5±6.9%; P<0.001).
A pproximately one third of patients with severe, symptomatic aortic stenosis (AS) have left ventricular (LV) systolic dysfunction. [1] [2] [3] [4] Surgical aortic valve replacement (SAVR) for patients with significant LV systolic dysfunction is beneficial but is associated with increased risk of hospital and long-term mortality when compared with patients with preserved LV function. 4, 5 LV recovery after SAVR has been demonstrated in over two thirds of patients with associated improved clinical outcomes 6 ; thus, SAVR is a viable option for treatment of selected patients with severe AS and LV systolic dysfunction.
Transcatheter aortic valve replacement (TAVR) is a mainstream therapy for patients at high or extreme risk for SAVR. [7] [8] [9] The response of patients with LV dysfunction to TAVR has become increasingly important: a recent UK TAVR registry demonstrates significant growth in TAVR utilization among patients with depressed LV systolic function, with ≈10% of contemporary TAVR patients having a baseline ejection fraction (EF) of <30%. 2 Recovery of LVEF and associated improvements in clinical outcomes has been demonstrated after both SAVR and Sapien TAVR, 1, [10] [11] [12] thus making TAVR a reasonable option in this high-risk group. 13, 14 A self-expanding aortic valve bioprosthesis may be an attractive treatment option in cases of LV compromise because it does not necessarily require balloon aortic valvuloplasty or pacemaker-induced hemodynamic instability. A potential clinical benefit of Corevalve TAVR in patients with depressed LV function has been identified in limited registry studies.
15, 16 The Corevalve High and Extreme-Risk trials included patients with significant LV dysfunction 7, 8 : the Left Ventricular Recovery After TAVR incidence, timing, and implications of CoreValve TAVR on LVEF recovery have not been previously described in these pivotal clinical trials.
Methods

Study Population
Patient selection for the CoreValve Extreme-Risk and High-Risk trials has been previously reported. 7, 8 For the CoreValve High-Risk trial, 795 patients were randomized to SAVR or TAVR at 44 sites; for the Extreme-Risk study, 639 patients underwent TAVR at 41 sites. As per trial protocols, patients had echocardiograms performed before TAVR, post procedure, and before discharge; follow-up echocardiograms were obtained at 30 days, 6 months, and 1 year. The trials were approved by the institutional review board at each site, and all patients provided written informed consent.
Patients were included based on the diagnosis of symptomatic severe AS. Echocardiographic diagnosis of severe AS was defined as an aortic valve area of <0.8 cm 2 or index of <0.5 cm 2 /m 2 and either a mean valve gradient of >40 mm Hg or peak aortic velocity of >4.0 m/s at rest or with a dobutamine stress echocardiogram if the LVEF was <50%. Dobutamine stress echocardiography was performed as previously described to confirm contractile reserve and mean aortic valve gradient of >40 mm Hg. [16] [17] [18] Principal exclusion criteria were active gastrointestinal bleed that would preclude anticoagulation, major stroke, or transient ischemic attack within 6 months, myocardial infarction (MI) or coronary artery intervention within 1 month, or life expectancy of <1 year because of comorbidities. Anatomic exclusion criteria included LVEF<20% on resting echocardiogram. A case summary was created for each patient that contained risk assessment, including comorbidities, hemodynamic criteria, and all imaging, which was reviewed and verified by a central laboratory. Each case was presented by the site heart team to the national screening committee; at least 2 senior cardiac surgeons and 1 interventional cardiologist had to agree that the patient met study eligibility, risk, and imaging criteria to be included in the study.
Echocardiographic Assessment
Echocardiography was performed using standard views, and chamber parameters were reported using standardized definitions. LVEF was measured using the biplane Simpson volumetric method combining apical 4-and 2-chamber views. Echocardiographic data are reported for all patients with data at each time point. Echocardiographic parameters include measures of systolic function (EF) and flow (stroke volume index) in addition to standard measures to assess severity of AS (gradient and valve area) and concomitant valvular heart disease. Early LVEF recovery was defined as a ≥10% improvement in EF comparing baseline with 30-day assessments. The ≥10% absolute improvement in EF was chosen to be consistent with a previous TAVR analysis in patients with mild to moderately decreased LV function.
1
Study End Points and Statistical Analysis
The primary end point of the CoreValve High-Risk trial was all-cause mortality; the primary end point of the Extreme-Risk trial was allcause mortality or major stroke. 7, 8 The current subgroup analysis determined the incidence of early LVEF recovery among the population of TAVR patients with clinically significant reductions in EF (EF 20%-40%). Patients were classified as early LVEF recovery (≥10% absolute increase in 30-day EF compared with baseline as assessed by core laboratory) or no-LVEF recovery group. The time course of LVEF recovery in each group from baseline to post procedure, 30 days, 6 months, and 1 year was compared among patients with and without early LVEF recovery; the analysis was repeated excluding patients who died during the first year to address potential survival bias. All follow-up echocardiograms were reviewed by an independent echocardiographic core laboratory (Mayo Clinic, Rochester, MN).
The early LVEF recovery and no-LVEF recovery groups were compared for baseline clinical, echocardiographic, and demographic parameters and differences in procedural variables. One-year clinical outcomes, including death, combined death and aortic valve hospitalization, and prespecified secondary trial end points, were compared between the 2 groups. Univariate predictors of 1-year mortality, including LVEF early recovery, were identified; a Cox proportional hazards model was performed to adjust for univariate baseline differences between the early LVEF recovery and no-LVEF recovery groups, including peripheral vascular disease, previous MI, and baseline mean gradient, to provide an adjusted analysis to determine the association between early LVEF recovery and 1-year death. All-cause mortality >12 months after TAVR was compared between the early LVEF recovery and no-LVEF recovery groups using Kaplan-Meier analysis, and a log-rank P value was calculated. A sensitivity analysis was performed comparing allcause mortality according to recovery of LV flow (as defined by 30-day stroke volume index >35 versus ≤35 mL). All patients included in these models were survived to 30-day assessment of LVEF recovery.
Univariate predictors of early LVEF recovery were identified from the baseline clinical and echocardiographic variables; stepwise multivariable logistic regression including all univariate predictors with P≤0.10 was performed to identify independent predictors of early LVEF recovery. Continuous variables are presented as mean±SD with comparisons made using the Student t test. Categorical variables were compared using the χ 2 or Fisher exact test. Ordinal variables were compared using the Cochran-Mantel-Haenszel test. Survival curves and other clinical outcomes are presented as Kaplan-Meier estimates. A 2-sided α level of 0.05 was used for all testing, and statistical analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC).
Results
Patient and Procedural Characteristics
One hundred fifty-six patients with severe AS and moderate to severe LV dysfunction met the criteria for the current analysis. Approximately two thirds of patients (62.2%) demonstrated early LVEF recovery at the 30-day assessment ( Figure 1 ) with a wide range in the degree of LVEF Recovery at day 30 (Figure 2) . The incidence and pattern of LVEF recovery remained similar when excluding patients who died during the first year of follow-up. Patients in both groups were of similar age and sex; multivessel coronary artery disease (CAD) was common in these patients with EF of <40% at baseline (89% of both groups; Table 1 ).
WHAT IS KNOWN
• Approximately one third of patients with severe, symptomatic aortic stenosis have left ventricular systolic dysfunction.
• Surgical aortic valve replacement is beneficial for these patients but is associated with increased risk of hospital and long-term mortality.
WHAT THE STUDY ADDS
• Early recovery of left ventricular ejection fraction occurs in approximately two thirds of patients after transcatheter aortic valve replacement and is associated with improved clinical outcomes.
• Early recovery after transcatheter aortic valve replacement is most likely among patients with higher baseline aortic valve gradients and no previous myocardial infarction. Left Ventricular Recovery After TAVR Baseline EF was similar in the 2 groups (≈32%), as was stroke volume index (≈35.0 mL/m 2 ; Table 2 ). Implant technique was similar in the 2 groups: rapid pacing was used in a minority of patients during valve deployment, as per protocol recommendations. Rapid pacing during implant (heart rate >120 bpm) was utilized in 27% of the no-LVEF recovery group when compared with 34% of the LVEF recovery group (P=0.35). Rapid pacing was used for preimplant balloon aortic valvuloplasty in 86% of patients (P=0.55 between groups). There was a significant difference in baseline mean aortic valve gradients: 34.5±9.5 mm Hg in the no-LVEF recovery group versus 42.3±14.0 mm Hg in the early LVEF recovery group (P<0.001). Moderate to severe mitral regurgitation tended to be more prevalent in the early recovery group: 28.4% versus 15.5% (P=0.07). Procedural approach and outcomes were similar in both groups-approximately three fourths of the patients had femoral access for TAVR implantation in both groups. Valve sizes spanned 26, 29, and 31 mm without differences between the groups. Pacemaker implantation was also similar (P=0.18). Moderate to severe paravalvular leak was uncommon (≈5.0%) after CoreValve TAVR and did not differ between the groups.
Recovery of LVEF: Time and Predictors
The time course of LVEF recovery is demonstrated in Figure 1 and shows a predominant pattern of significant EF recovery within 48 hours of implantation. Among all patients with moderate to severe baseline LV systolic dysfunction, there was little change from 48 hours post TAVR (65.7%) to 1 year post TAVR (70.0%) in the overall frequency of LVEF recovery. The recovery curve remained similar when the analysis was confined to patients surviving Histogram demonstrating early left ventricular ejection fraction (LVEF) recovery as a function of the percent change and frequency of patients with recovery. The analysis was done by 5% increments as visual estimates were used for assessing change in EF and a broad range of change in EF is observed. Left Ventricular Recovery After TAVR to 1-year follow-up. Recovery of LVEF was not statistically different at 30 days regardless of baseline flow as measured by stroke volume index: 65.8% of patients with baseline index of ≤35 mL/m 2 and 58.5% of patients with baseline index of >35 mL/m 2 (P=0.39). At baseline, the LVEF recovery and no-LVEF recovery groups had similar EF, stroke volume index, and LV end-systolic dimension ( (Table 3 ). This pattern was persistent at each echocardiographic time point. Of note, patients with no-early LVEF recovery did demonstrate a significant albeit more modest improvement in EF over the course of the year, from 32.9±6.2% at baseline to 43.3±12.3% at 1 year (P<0.001). The dynamic changes in the incidence of LVEF recovery at each time point are illustrated in Figure 3 .
Of the 156 patients with LV dysfunction enrolled in this study, 31% (n=48) had a mean resting gradient of <40 mm Hg. All of these patients demonstrated contractile reserve with dobutamine echocardiography, as patients without adequate contractile reserve were not enrolled in these 2 trials. Contractile reserve was defined as an augmented mean gradient of >40 mm Hg with escalating doses of dobutamine Data are mean±SD (n) or % (n/N). LVEF indicates left ventricular ejection fraction; and TAVR, transcatheter aortic valve replacement. Left Ventricular Recovery After TAVR (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) μg/kg per minute). Of note, simultaneous augmented LVEF was not considered a requirement for inclusion in the trials. Patients with a resting mean gradient of >40 mm Hg had an increased association with early LVEF recovery at 30 days after TAVR: 51% of patients undergoing dobutamine confirmation of contractile reserve had LVEF recovery when compared with 67% of patients with a resting mean gradient of >40 mm Hg (P=0.05). Multivariable logistic regression identified 1 positive and 1 negative predictor of early LVEF recovery: baseline mean gradient of >40 mm Hg (odds ratio, 4.59; 95% confidence interval, 1.76-11.96) and previous MI (odds ratio, 0.44; 95% confidence interval, 0.19-1.03; Table 4 ). CAD and baseline stroke volume index did not predict LVEF recovery.
Finally, a lower limit cutoff value could not be identified with respect to resting mean aortic valve gradient and early LVEF recovery. Average mean gradients were higher at baseline in the recovery than in the no-LVEF recovery group (P<0.001). But resting baseline mean aortic valve gradients in the early LVEF recovery group ranged from 18 to 82 mm Hg ( Figure 4) . As per the trial design, all patients in both groups had a mean gradient of >40 mm Hg after dobutamine echocardiographic assessment.
Recovery of LVEF and Clinical Outcomes
For the 156 patients with reduced LVEF in this study, the LVEF improved from 32±7.0% to 42.3±11.7% 30 days after TAVR (P<0.0001). One-year all-cause mortality tended to be higher (but not statistically significant) in patients without early LVEF recovery than in those with early LVEF recovery (23.7% versus 12.4%; P=0.07) ( Figure 5 ). In addition to Kaplan-Meier analysis, we performed a Cox proportional hazards model to adjust for univariate differences between the early recovery and no-early recovery group (including peripheral vascular disease, baseline mean gradient >40 mm Hg, and previous MI). The results were consistent with the unadjusted mortality comparison: the hazard ratio for 1-year all-cause mortality was 0.58 in the early LVEF recovery versus noearly LVEF recovery group (95% confidence interval, 0.26-1.31; P=0. 19) .
When analyzed according to recovery of stroke volume index of >35 mL/m 2 at day 30 (cardiac flow) as opposed to stroke volume index of ≤35 mL/m 2 , 1-year mortality was not statistically different (13.5% versus 22.2%, respectively; P=0.17). Cardiovascular mortality was not significantly higher in the no-LVEF recovery group than in the LV recovery group (12.4% versus 10.4%; P=0.72), and we note that there were only 17 total cardiovascular deaths in this substudy. Hospitalizations related to aortic valve disease tended to be higher (but not statistically significant) in the no-LVEF recovery than in the early LVEF recovery groups: 38.4% versus 22.0% (P=0.08). The combined end point of any death or repeat hospitalization for aortic valve failure was significantly higher in the no-LVEF recovery group: 47.5% versus 26.8% (P=0.021).
Rates of stroke (6.8% versus 6.4%; P=0.83) and major bleeding (30.8% versus 30.3%; P=0.31) were nearly identical in the early LVEF recovery versus no-early LVEF recovery groups, respectively. The rates of acute kidney injury were also similar in the 2 groups (15.3% versus 11.3%; P=0.46, in the recovery versus no-recovery groups, respectively). Of note, no patient in either group had class IV congestive heart failure at 1-year assessment. Quality of life, assessed by the Kansas City Cardiomyopathy Questionnaire overall summary score, improved similarly in both groups at 1 year after TAVR: 28.4±30.7 versus 21.8±32.1 for the no-early LVEF recovery and early LVEF recovery groups, respectively (P=0.33).
Discussion
This subgroup analysis of the pivotal High-Risk and ExtremeRisk CoreValve trials represents the largest reported study of LVEF recovery in any TAVR trial population. Our study contributes 3 main findings to the understanding of LV systolic function recovery after TAVR: (1) 
Temporal Trends in Recovery of LVEF
Our observations of temporal trends in LV recovery are consistent with previous findings from the Placement of Aortic Transcatheter Valve (PARTNER) trials. 1, 11 Although these studies included patients with lesser degrees of LV systolic dysfunction (ie, EF 40%-50%), the general finding of a rapid recovery is similar: in PARTNER A, ≈50% of patients demonstrated early LVEF recovery (≥10% absolute increase in EF at 30-day follow-up after Sapien TAVR). Our finding of a high rate (62%) of early LVEF recovery may portend a role for the CoreValve TAVR procedure in these patients with low EF. This advantage may be related to differences in valve design, patient characteristics, or may reflect a lower baseline EF in the current study when compared with previous analyses of this high-risk group.
Our findings also concur with the PARTNER trial findings on the time course of LVEF recovery between 30 days and 1 year 1 : the mean EF between 30 days and 1 year after 
Consequences and Prediction of Early LVEF Recovery
Patients without early LVEF recovery were generally at higher risk for clinical events, including trends toward higher mortality and aortic valve failure-related hospitalizations. A known association exists between baseline LV dysfunction and mortality after both SAVR and TAVR. 3, 4 Similarly, baseline LV systolic dysfunction has been shown to be an independent predictor of early repeat admissions after TAVR. 19 Our results may help clinicians reclassify this risk for 1-year mortality and early repeat admissions after TAVR based on assessment of early LVEF recovery. Our findings that early LVEF recovery portends an improved prognosis is consistent with similar findings in SAVR patients 6 and in Sapien TAVR patients.
1
Two independent predictors of early LVEF recovery after CoreValve TAVR implantation were identified in this analysis. First, patients with a baseline mean gradient of >40 mm Hg were >3× likely to have early LVEF recovery than those with lower baseline mean gradients. This is consistent with the findings from the PARTNER trial, which similarly showed a continuous relationship between mean gradient and LVEF recovery. 1 Our findings are notable, although, for the wide range of baseline resting mean gradients associated with LVEF recovery (18-82 mm Hg); thus, no appreciable cutoff value could be defined that would a priori suggest LVEF recovery was impossible. Of note, our study cannot comment on the entire complex patient group with low-flow/low-gradient AS (with reduced or preserved EF). 17, 20, 21 All patients in the current study have both an EF of ≤40% and a mean gradient of . All-cause mortality over the first year after CoreValve transcatheter aortic valve replacement stratified according to early left ventricular ejection fraction (LVEF) recovery (≥10% improvement at day 30) with numerically higher mortality rate in the no-early LVEF recovery group. Left Ventricular Recovery After TAVR >40 mm Hg (at rest or after dobutamine echocardiography), so the syndrome of paradoxical low-flow/low-gradient AS cannot be examined. In addition, our study excluded patients with an EF of <20% and an EF of 40% to 50%: this may lead to an under-representation of the entire population of LV dysfunction patients undergoing TAVR.
The second independent predictor of early LVEF recovery after CoreValve TAVR was the presence of previous MI. The concept that previous myocardial damage would be correlated with failure to improve EF is plausible. Previous infarction was defined by clinical history: the extent of myocardial damage as assessed by cardiac myocardial resonance imaging might provide further insights into prognosis. Previous studies have suggested that previous MI and CAD are both associated with worse prognosis after TAVR in the setting of LV dysfunction.
18,22-24 Our study did not find CAD to be a predictor of noearly LVEF recovery: Further clarification of extent of CAD and residual ischemic burden after protocol-mandated percutaneous coronary intervention might provide further insight into the impact of CAD on TAVR outcomes in patients with LV systolic dysfunction. 25, 26 We note that procedural variables (ie, pacemaker requirement, valve size, and paravalular leak) were not predictors of early LVEF recovery. Other studies have suggested that moderate to severe paravalvular regurgitation is associated with increased mortality in patients with LV dysfunction undergoing TAVR 10 ; the low rate of moderate to severe paravalvular leak (5%) in the current analysis limits the ability to associate this complication with LVEF recovery or 1-year mortality. In fact, there were 0 cases of severe paravalvular leak and only 8 cases of moderate paravalvular leak preventing any conclusive statements on the association of this complication with LVEF recovery.
Similarly, there was a numeric but nonstatistically significant trend toward higher incidence of no-LVEF recovery in the group of patients in which TAVR was complicated by pacemaker requirement (38% versus 24%; P=0.18). It is possible that a larger sample size would demonstrate LV recovery is hindered by a lack of atrial-ventricular synchrony and the need for a pacemaker, as has been suggested in previous registry study. 27 Furthermore, we have not analyzed the relationship of other conduction defects (ie, transient or permanent left bundle branch block) with LVEF recovery because of the relatively small sample size of this substudy. Previous observations on the importance of pacemakers and conduction defects warrant further study as (1) differences in 1-year mortality associated with conduction abnormalities or new pacemaker requirement after TAVR are unclear [28] [29] [30] and (2) over half of TAVR patients receiving a pacemaker are in normal sinus rhythm 30 days after TAVR and thus are not hindered by a persistently paced rhythm.
31,32
Limitations
Our study is limited by a relatively small sample size, which may limit statistical significance in the prediction models. Although our sample size (n=156) is relatively small, this is the largest trial of patients with LV dysfunction undergoing TAVR analyzed to date. Our study population could have been amplified by including patients with mild LV dysfunction (EF, 40%-50%); we chose a sample with EF of ≤40% to correspond with previous studies in the systolic heart failure literature. Our study cannot comment on the relative benefit of CoreValve TAVR versus SAVR on early LVEF recovery as we deliberately included the single-arm extreme-risk cohort to maximize the sample size, preventing comparison with a randomized SAVR cohort. The comparison of TAVR versus SAVR in this patient population has been done previously in both clinical trials and registries using the Sapien TAVR device, and those studies demonstrate inconsistent results. 1, 14 The strength of our study is that our observations are generated from a relatively homogeneous trial population of patients with clinically significant LV systolic dysfunction, and each patient underwent rigorous core laboratory echocardiographic measurements at defined time points per a clinical trial protocol.
Conclusions
In the largest clinical trial analysis of TAVR among patients with LV systolic dysfunction, we demonstrate early LVEF recovery in approximately two thirds of patients and associated improvements in clinical outcomes. Patients with baseline mean gradients of >40 mm Hg and patients without previous MI were most likely to have early LVEF recovery, but there was no clear lower limit of resting aortic valve gradients that defined a no-recovery group.
